查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1422854

2024-2032 年按類型、配銷通路、應用和地區分類的免疫檢查點抑制劑市場報告

Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

2023年全球免疫檢查點抑制劑市場規模達431億美元。展望未來， IMARC Group預計到2032年市場規模將達到1,572億美元，2024-2032年複合年成長率（CAGR）為15.01%。各種癌症盛行率的上升、呼吸系統疾病發生率的增加以及對個人化藥物的日益偏好是推動市場發展的一些關鍵因素。

免疫檢查點抑制劑是一種透過抑制免疫系統細胞（例如 T 細胞和癌細胞）產生的特定蛋白質來治療癌症的藥物。它們可以單獨使用，也可以與其他癌症治療方法（例如化療和放射治療）結合使用，以增強治療效果。它們透過減少疾病症狀並延長癌症患者的生存期來幫助提高癌症患者的生活品質。免疫檢查點抑制劑針對免疫系統中的特定途徑，從而實現更有針對性的癌症治療方法。與傳統化療相比，這些抑制劑的毒性較低，副作用較少，患者的耐受性較好。目前，擴大使用新一代定序技術來識別癌細胞中的特定基因突變，從而刺激了全球對免疫檢查點抑制劑的需求。

免疫檢查點抑制劑市場趨勢：

黑色素瘤、肝癌、腎癌和胃癌等各種癌症在個體中的盛行率激增，是推動全球免疫檢查點抑制劑需求的主要因素之一。此外，人口老化的加劇，更容易罹患這種嚴重的癌症，以及肥胖症盛行率的上升，有利於市場的成長。此外，由於酒精飲料和菸草製品消費量的增加，呼吸系統疾病的發生率也有所增加。再加上由於不健康的飲食習慣和久坐的生活方式而引起的與體重相關的健康問題日益增多，正在對市場產生積極影響。除此之外，各種遺傳和生活方式疾病的激增以及個人和醫療保健專業人員對癌症早期診斷和治療的好處的認知不斷提高，正在推動市場的成長。此外，製藥公司臨床試驗數量的不斷增加以及對個人化藥物和新一代藥物和製劑的日益青睞正在推動市場的成長。除此之外，領導企業越來越注重策略合作和新產品開發，以擴大其產品組合併獲得競爭優勢，這為市場創造了積極的前景。此外，醫療基礎設施和診斷技術的顯著改善預計將加強市場的成長。

本報告回答的關鍵問題

  • 全球免疫檢查點抑制劑市場有多大？
  • 2024-2032年全球免疫檢查點抑制劑市場的預期成長率是多少？
  • 推動全球免疫檢查點抑制劑市場的關鍵因素是什麼？
  • COVID-19對全球免疫檢查點抑制劑市場有何影響？
  • 全球免疫檢查點抑制劑市場按類型分類是怎樣的？
  • 基於配銷通路的全球免疫檢查點抑制劑市場的詳細情形如何？
  • 基於應用的全球免疫檢查點抑制劑市場的細分如何？
  • 全球免疫檢查點抑制劑市場的重點區域有哪些？
  • 全球免疫檢查點抑制劑市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球免疫檢查點抑制劑市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按類型

  • CTLA-4抑制劑
    • 市場走向
    • 市場預測
  • PD-1抑制劑
    • 市場走向
    • 市場預測
  • PD-L1抑制劑
    • 市場走向
    • 市場預測

第 7 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥局
    • 市場走向
    • 市場預測
  • 網路藥局
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按應用

  • 肺癌
    • 市場走向
    • 市場預測
  • 膀胱癌
    • 市場走向
    • 市場預測
  • 黑色素瘤
    • 市場走向
    • 市場預測
  • 大腸直腸癌
    • 市場走向
    • 市場預測
  • 霍奇金淋巴瘤
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • GSK plc
    • Merck & Co. Inc.
    • Ono Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • Seagen Inc.
Product Code: SR112024A7221

Abstract

The global immune checkpoint inhibitors market size reached US$ 43.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 157.2 Billion by 2032, exhibiting a growth rate (CAGR) of 15.01% during 2024-2032. The rising prevalence of various cancers, increasing incidences of respiratory disorders, and the growing preference for personalized medicines represent some of the key factors driving the market.

Immune checkpoint inhibitors are drugs utilized for treating cancer by inhibiting specific proteins made by immune system cells, such as T cells and cancer cells. They are either used alone or in combination with other cancer treatments, such as chemotherapy and radiation therapy to enhance treatment outcomes. They aid in enhancing the quality of life for cancer patients by reducing the symptoms of the disease and extending their survival. Immune checkpoint inhibitors target specific pathways in the immune system, which enables a more targeted approach to cancer treatment. These inhibitors have a lower toxicity profile that leads to fewer side effects and better tolerance to patients as compared to traditional chemotherapy. At present, the rising use of next-generation sequencing technologies that enables the identification of specific genetic mutations in cancer cells is catalyzing the demand for immune checkpoint inhibitors across the globe.

Immune Checkpoint Inhibitors Market Trends:

The surging prevalence of various cancers among individuals, such as melanoma, liver, kidney, and gastric, represents one of the major factors driving the demand for immune checkpoint inhibitors around the world. Moreover, the increasing aging population, which is more prone to develop such severe cancers and the rising prevalence of obesity is favoring the market growth. In addition, there is an increase in the incidences of respiratory disorders on account of the rising consumption of alcoholic beverages and tobacco-based products. This, coupled with the growing numbers of weight-related health concerns on account of unhealthy eating habits and sedentary lifestyles, is influencing the market positively. Apart from this, the surging occurrence of various genetic and lifestyle diseases and the increasing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of cancer is propelling the growth of the market. Furthermore, the expanding number of clinical trials by pharmaceutical companies and the rising preference for personalized medicines and new generation drugs and formulations are propelling the growth of the market. Besides this, the growing focus of leading players on strategic collaborations and new product developments to expand their product portfolio and gain a competitive edge is creating a positive outlook for the market. Additionally, significant improvements in medical infrastructure and diagnostic technologies are anticipated to strengthen the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global immune checkpoint inhibitors market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type, distribution channel, and application.

Type Insights:

CTLA-4 Inhibitor

PD-1 Inhibitor

PD-L1 Inhibitor

The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the type. This includes CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. According to the report, PD-1 inhibitor represented the largest segment.

Distribution Channel Insights:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the immune checkpoint inhibitors market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Application Insights:

Lung Cancer

Bladder Cancer

Melanoma

Colorectal Cancer

Hodgkin Lymphoma

Others

The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the application. This includes lung cancer, bladder cancer, melanoma, colorectal cancer, Hodgkin lymphoma, and others. According to the report, lung cancer represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for immune checkpoint inhibitors. Some of the factors driving the North America immune checkpoint inhibitors market included the increasing aging population, presence of a well-established healthcare infrastructure, rising research and development (R&D) activities, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global immune checkpoint inhibitors market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., etc.

Key Questions Answered in This Report

  • 1. How big is the global immune checkpoint inhibitors market?
  • 2. What is the expected growth rate of the global immune checkpoint inhibitors market during 2024-2032?
  • 3. What are the key factors driving the global immune checkpoint inhibitors market?
  • 4. What has been the impact of COVID-19 on the global immune checkpoint inhibitors market?
  • 5. What is the breakup of the global immune checkpoint inhibitors market based on the type?
  • 6. What is the breakup of the global immune checkpoint inhibitors market based on the distribution channel?
  • 7. What is the breakup of the global immune checkpoint inhibitors market based on the application?
  • 8. What are the key regions in the global immune checkpoint inhibitors market?
  • 9. Who are the key players/companies in the global immune checkpoint inhibitors market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immune Checkpoint Inhibitors Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 CTLA-4 Inhibitor
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 PD-1 Inhibitor
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 PD-L1 Inhibitor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Lung Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Bladder Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Melanoma
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Colorectal Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Hodgkin Lymphoma
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bristol-Myers Squibb Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 GSK plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Ono Pharmaceutical Co. Ltd.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Regeneron Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Seagen Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Immune Checkpoint Inhibitors Market: Major Drivers and Challenges
  • Figure 2: Global: Immune Checkpoint Inhibitors Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Immune Checkpoint Inhibitors Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Immune Checkpoint Inhibitors Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Immune Checkpoint Inhibitors Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Immune Checkpoint Inhibitors Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Immune Checkpoint Inhibitors (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Immune Checkpoint Inhibitors (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Immune Checkpoint Inhibitors (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Immune Checkpoint Inhibitors (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Immune Checkpoint Inhibitors Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Immune Checkpoint Inhibitors Industry: Drivers, Restraints, and Opportunities
  • Figure 82: Global: Immune Checkpoint Inhibitors Industry: Value Chain Analysis
  • Figure 83: Global: Immune Checkpoint Inhibitors Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immune Checkpoint Inhibitors Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Immune Checkpoint Inhibitors Market: Competitive Structure
  • Table 7: Global: Immune Checkpoint Inhibitors Market: Key Players